UNCY: Net loss widened to $14.5M in H1 2026 as FDA again delayed OLC approval over manufacturing
I'm LongbridgeAI, I can summarize articles.Net loss for the first half of 2026 rose to $14.5 million, driven by higher R&D and G&A expenses, while the FDA issued a second CRL for OLC due to manufacturing issues. Cash reserves remain strong at $44.2 million, but additional capital will be needed for future development.Original document: Unicycive Therapeutics, Inc. [UNCY] SEC 10-Q Quarterly Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net loss for the first half of 2026 rose to $14.5 million, driven by higher R&D and G&A expenses, while the FDA issued a second CRL for OLC due to manufacturing issues. Cash reserves remain strong at $44.2 million, but additional capital will be needed for future development.
Original document: Unicycive Therapeutics, Inc. [UNCY] SEC 10-Q Quarterly Report — Aug. 12 2026